Enanta Pharmaceuticals Inc (ENTA) receives an Underweight rating from JP Morgan

Enanta Pharmaceuticals Inc’s recent filing unveils that its President and CEO Luly Jay R. acquired Company’s shares for reported $0.26 million on Feb 12 ’25. In the deal valued at $5.69 per share,45,000 shares were bought. As a result of this transaction, Luly Jay R. now holds 846,638 shares worth roughly $5.58 million.

Then, Kieffer Tara Lynn sold 2,283 shares, generating $18,401 in total proceeds. Upon selling the shares at $8.06, the Chief Product Strategy Officer now owns 29,305 shares.

Before that, Luu Brendan sold 2,283 shares. Enanta Pharmaceuticals Inc shares valued at $18,401 were divested by the Chief Business Officer at a price of $8.06 per share. As a result of the transaction, Luu Brendan now holds 36,047 shares, worth roughly $0.24 million.

JP Morgan downgraded its Enanta Pharmaceuticals Inc [ENTA] rating to an Underweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who decreased its forecast for the stock in early August from “a Buy” to “a Hold”. H.C. Wainwright began covering ENTA with “Buy” recommendation on December 09, 2022. Evercore ISI revised its rating on July 06, 2022. It rated ENTA as “an Outperform” which previously was an “an In-line”.

Price Performance Review of ENTA

On Tuesday, Enanta Pharmaceuticals Inc [NASDAQ:ENTA] saw its stock fall -5.32% to $6.59. Over the last five days, the stock has lost -14.97%. Enanta Pharmaceuticals Inc shares have fallen nearly -56.04% since the year began. Nevertheless, the stocks have risen 14.61% over the past one year. While a 52-week high of $17.24 was reached on 02/24/25, a 52-week low of $4.09 was recorded on 04/09/25.

Levels Of Support And Resistance For ENTA Stock

The 24-hour chart illustrates a support level at 6.37, which if violated will result in even more drops to 6.15. On the upside, there is a resistance level at 6.91. A further resistance level may holdings at 7.22.

How much short interest is there in Enanta Pharmaceuticals Inc?

A steep rise in short interest was recorded in Enanta Pharmaceuticals Inc stocks on 2025-06-13, dropping by -0.36 million shares to a total of 2.5 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 2.85 million shares. There was a decline of -14.24%, which implies that there is a negative sentiment for the stock.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.